Biaryl amide compounds as kinase inhibitors

US9242969B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Paul A. Barsanti · Emeryville, US
• Matthew Burger · Belmont, US
• Yan Lou · Fremont, US
• Gisele Nishiguchi · Arlington, US
• Valery Rostislavovich POLYAKOV · Moraga, US
• Savithri Ramurthy · Walnut Creek, US
• Alice Rico · Castro Valley, US
• Lina Q. Setti · Fremont, US
• Aaron Smith · Fremont, US
• Benjamin R. TAFT · Lafayette, US
• Huw Tanner · San Francisco, US
• Alan Dipesa · Brookline, US
• Naeem Yusuff · Cambridge, US

Key dates

• Filing date: Mar 11, 2014
• Grant date: Jan 26, 2016
• Expiry date: Mar 11, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I)as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.